
AN2 Therapeutics, Inc.: updates and filings
Price
$5.08
November 20, 2026Market cap $193M
What Ploutos Investor adds for AN2 Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 27% since Nov 9, 2026, when the 10-Q these figures come from was filed ($4.00 then, $5.08 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
June 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Sep 14, 2026Shares registered for employeesFormS-8
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jun 9, 2026Shareholder voteForm8-K
- Jun 4, 2026Regulation FD disclosure, other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operationsForm8-K
- Apr 22, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Annual meeting proxy statementFormDEF 14A
- Apr 20, 2026FilingFormEFFECT
- Apr 16, 2026Correspondence with the SECFormCORRESP
- Apr 15, 2026Letter from the SECFormUPLOAD
- Apr 9, 2026Shelf registration for future offeringsFormS-3
- Apr 9, 2026Other material eventsForm8-K
- Mar 25, 2026FilingFormD
- Mar 20, 2026Officer or director changeForm8-K
- Mar 17, 2026Shares registered for employeesFormS-8
- Mar 17, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Sep 14, 2026 | S-8 | Shares registered for employees | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jun 9, 2026 | 8-K | Shareholder vote | Document |
| Jun 4, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| Apr 22, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 20, 2026 | EFFECT | Filing | Document |
| Apr 16, 2026 | CORRESP | Correspondence with the SEC | Document |
| Apr 15, 2026 | UPLOAD | Letter from the SEC | Document |
| Apr 9, 2026 | S-3 | Shelf registration for future offerings | Document |
| Apr 9, 2026 | 8-K | Other material events | Document |
| Mar 25, 2026 | D | Filing | Document |
| Mar 20, 2026 | 8-K | Officer or director change | Document |
| Mar 17, 2026 | S-8 | Shares registered for employees | Document |
| Mar 17, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 24, 2021.
The full analysis
What do AN2 Therapeutics's filings show?
The filings are where every one of AN2 Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.